Wepresenttheandrogenreceptor(AR)statusin32breastcancersdiagnosedin malepatients.Androgenreceptorexpressionwasfoundin62.5%tumorsandit wasmorefrequent(85%ofcases)inestrogen-positivetumours.Theanalysesofits impactontreatmentresultsshowedthatARimmmunopositivityisaprognostic factorforoverallsurvival,andARimmunonegativityisalsocorrelatedwithworse prognosis(distantmetastasesdevelopedmorefrequentlyandearlier).
Introduction
Male breast cancer is a very rare malignant neoplasmwithanincidencerateof0.1-1% [1, 2, 3] .The biologicalfactorsofmalebreastcanceraresimilarto those present in female variant, however, some differences were noted [4, 5, 6] . Male breast cancer, incomparisontofemalevariant,ischaracterisedby more advanced stage, well-differentiated histology (G1, G2), and higher frequency of hormone receptors expression [2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14] .Moreover,itischaracterisedbyworseprognosis [4, 5, 6, 15] .Availableliteraturedataandtheresults of our earlier study show that nodal involvement andhormonereceptorstatusarethemostimportant prognosticfactorsinmalepatientswithbreastcancer [5, 9, 11, 13, 14, 15, 16, 17] .Ourobservations showedacorrelationbetweenhormonereceptor(estrogenreceptor[ER]/progesteronereceptor[PgR]) immunonegativity and poor prognosis (relative risk was4.12and6.94foroverallanddisease-freesurvival,respectively) [16] .Androgenreceptor(AR),which playsaroleintheinhibitionofestrogen-dependent signalling,isapotentialprognosticmarkerinbreast cancer [2, 18, 19, 20, 21] .Someclinicaldatasuggest thatARpositivitywouldmodifyclinicaloutcomesin breastcancerpatients [22, 23, 24] .
Theaimofthepresentstudywastoassess:(i)AR status with regard to the frequency of its immunopositivity, (ii) correlation between AR status and clinicopathological parameters, and (iii) the impact onoverallanddisease-freesurvival.
Material and methods

Patients
Between 1950 and 2010, 17320 patients with breast cancer were treated at the Maria Skłodow-ska-Curie Memorial Cancer Center and Institute of Oncology in Krakow. Among them there were 81 (0.5%)malepatients;detailedcharacteristicsofthis group was presented in our earlier papers [16, 25, 26] 
Immunohistochemistry
The expression of AR was assessed on formalin-fixed paraffin-embedded tissue sections, which werecutat4μmandmountedonSuperFrost; Plus (Menzel-Gläser, Germany) slides and then deparaffinizedandhydratedthroughaseriesofxylenesand alcohols.
After antigen unmasking (Target Retrieval Solution, pH = 6.1 DakoCytomation Denmark A/S, Glostrup, Denmark: 50 min, 96 o C), slides were incubatedfor30min.in0.3%H 2 O 2 dilutedinmethanol.Non-specificbindingofantibodieswasblocked during 5 min. incubation with UltraVision Protein Block (Thermo Scientific, Fremont, USA). After incubation with primary antibody (diluted 1 : 50), BrightVisiondetectionsystem(Immunologic,Duiven,TheNetherlands)andDAB(VectorLaboratories, Inc.,Burlingame,USA)wereapplied.Finally,hematoxylin was used for nuclear counterstaining. Each stepofthestainingprocedurewasfollowedbywashing in Tris-Buffered Saline and Tween 20 (TBST).
Thedetailsofotherimmunohistochemicalstainings werepresentedelsewhere [16] .
WedidnotobtainIHCresultsforallproteinsin allcasesbecauseofinadequateamountoftumourtissuethathinderedobtainingreliableresults.
IHC evaluation
The presence of AR was evaluated exclusively in theinvasivecomponentofthetumours.Immunopositivity of AR was classified as previously described [27] -morethan50%tumourcellswithweakstain-ingoranypercentagewithmoderate/strongstaining. The details of other immunohistochemical evaluationswerepresentedelsewhere [16] .
Statistical methods
AllcalculationswereperformedbySTATISTICA v.10software(StatSoft,Inc.Tulsa,OK,USA)andthe significancelevelforallthetestswassetasα=0.05. Differences between two groups (AR immunonegativity and AR immunopositivity) were tested using theMann-WhitneyU-test(forcontinuousvariables) andPearson'sχ 2 test(forcategorizedvariables).The probability of overall survival (OS) and disease-free survival(DFS)wereestimatedusingtheKaplan-Meier method. The log-rank test was applied to assess the influence of AR status on the treatment results (OSandDFS).
Results
The androgen receptor (AR) immunopositivity was noted in 20 cases (62.5%), while in 6 tumours immunonegativity was observed. Examples of AR stainingresultsareshowninFig.1.
The comparison of clinicopathological characteristicsaccordingtoARstatusispresentedinTableI.
Androgen receptor immunonegativity was found inallcarcinomaswithoutERexpression,while85% Fig.2A)andDFS(p=0.062,Fig.2B ). Theestimated5-yearOSandDFSratesforARpositivity was 62.9% and 77.4%, while for AR negativity-33.3%and25%,respectively.Theabsolute improvementofOSandDFSat5yearswas29.6% and52.4%,respectively,butonlyincaseofOSitwas statisticallysignificant(p=0.045).
ThispositiveinfluenceofARimmunopositivityon treatmentoutcomewasconfirmedbytheresultsofan analysisofdistantmetastasesoccurrence.InAR-posi- 
Discussion
Androgen receptor is a mediator of androgen action in androgen-response tissues (prostate and breast). AR plays an essential role in the developmentandmaintenanceofnormalglandularorganizationandintegrity.AberrantARresponsescanlead tothedisruptionresultingintumorigenesis [28] .AR positivityisdetectedinapproximately70-80%ofall breast cancer cases and it is associated with favourable outcomes, especially in patients with ER-positivetumors [2, 19, 29, 30, 31, 32] .
Inourmaterial,ARpositivitywasnotedin62.5% ofanalysedcasesandwasrelatedtofavourableoverallanddisease-freesurvival.Theabsolutebenefitat 5yearswas29.6%forOSand52.4%forDFS,but only differences in OS were statistically significant. Similarresultswerenotedbyotherauthors,whoreportedthatabsolutedifferencesinprobabilityofOS at3and5yearswere6.7%and13.5%,respectively, whileforDFS-8.8%and20.7%,respectively [22] . However, these results were observed in female patients.Becauseoflowincidenceofmalebreastcancer andthelackofpublicationsinthisarea,wereferred toliteratureconcerningfemalebreastcancer.Inone of the studies it was found that AR negativity predictedtheoccurrenceofdistantmetastases [23] .On the other hand, Wenhui et al. noted adverse effect ofARpositivityanditscorrelationwithpoorclinical outcome(bothoverallanddisease-freesurvival) [33] . Vera-Badillo et al. hypothesized that AR positivity is a good prognostic marker in ER-positive tumors andapoorprognosticmarkerinER-negativetumors [22] . However, the aforementioned hypothesis was notconfirmedinmeta-analysis.
WenotedsignificantcorrelationbetweenARpositivity and expression of other steroid receptors (estrogen,progesterone).Inourseries,85%oftumors withARpositivitywereERimmunopositive.Other researchers, similarly to us, noted this relationship. Intheirstudy,74.8%ofER-positivetumorsshowed AR expression [22] . Moreover, similarly to us, other studies reported that high expression of AR was not correlated with T stage, histological grade and the status of other hormone receptors [34] . Other authorsobservedthatARtoERratiomayinfluence breast cancer response to hormonal therapy [31] . HighARtoERratio(≥2)isrelatedtoincreasingrisk of failure after tamoxifen application. Additionally, this ratio correlates with lymph node involvement and with lower value of proliferation index (MIB-1 LI),anditisanindependentpredictorofDFS [31] .
Furthermore,ARexpressionnegativelycorrelates withexpressionofKi-67 [24] ,TP53 [35] andwith lackofexpressionofcytokeratine5/6 [34] andE-cadherin [32] .Theseresultsareconsistentwiththefact thatAR-positivetumorsarewell-differentiated [31] , whileAR-negativeonesmetastasisemorefrequently [23] .
Ourobservationsweresimilar,however,thedifferences did not reach statistical significance. We noted that AR positivity (in comparison with AR negativity) characterised well differentiated carcinomas (G1:30%vs.16.7%)andtumourswithlowerproliferationindex(meanvalueofMIB-1LI:33.1%vs. 41.6%).Moreover,lesspatientswithAR-positivetumoursdevelopeddistantmetastases(30%vs.50%), whichalsooccurredlater(80monthsvs.10months after treatment) than in patients with AR-negative carcinomas. OtherclinicalobservationsshowedthatARnegativitywasassociatedwithshorterDFSandOS,especiallyincaseoftriplenegativebreastcancer [32, 35, 36] .TheseresultssuggestthatARexpressioncould beausefulprognosticmarkerintriplenegativetumorsanditmaybeconsideredasoneofthemarkers ofthissubtype [23, 37] .
Conclusions
Androgen receptor in male breast cancer is expressed: (i) frequently (by 62.5% of tumors), and (ii) more often in tumours with estrogen receptor positivity(in85%ofER+carcinomas).Moreover,its expressionisapositiveprognosticmarkerforoverall anddisease-freesurvival.
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